Ajinomoto Bio-Pharma Services vs Novartis: CDMO Comparison
How does Ajinomoto Bio-Pharma Services compare to Novartis for Gene Therapy manufacturing?
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (15 vs 0) — a deeper regulatory paper trail.
- Novartis holds 59 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Novartis has stronger MHRA / UK coverage (3 compliant certificates vs 1).
- Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Novartis qualify as Gene Therapy manufacturers; Novartis carries the higher composite Signal Score for Gene Therapy programs in this comparison.
What to evaluate for Gene Therapy programs
Both Ajinomoto Bio-Pharma Services and Novartis qualify as Gene Therapy CDMOs. When choosing between them for Gene Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Frequently asked: Ajinomoto Bio-Pharma Services vs Novartis
How does Ajinomoto Bio-Pharma Services compare to Novartis for Gene Therapy manufacturing?
On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 86/100 and Novartis is 88/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 15 for Novartis; European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 62 for Novartis. Both are tracked in the CDMO Signal directory as Gene Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Novartis?
Ajinomoto Bio-Pharma Services has 0 FDA inspections on record (NAI 0 / VAI 0 / OAI 0) and 0 warning letters. Novartis has 15 FDA inspections on record (NAI 6 / VAI 7 / OAI 2) and 0 warning letters.
How do Ajinomoto Bio-Pharma Services and Novartis compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Novartis holds 59 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Ajinomoto Bio-Pharma Services or Novartis?
Ajinomoto Bio-Pharma Services is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 137. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Gene Therapy manufacturing — Ajinomoto Bio-Pharma Services or Novartis?
Both Ajinomoto Bio-Pharma Services and Novartis are tagged as Gene Therapy CDMOs in our directory, so both are credible options for Gene Therapy programs. The most important differentiator for Gene Therapy selection is typically vector platform match: The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →